{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:28:04Z","timestamp":1786472884062,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"the Deutsche Forschungsgemeinschaft (DFG)"},{"name":"SFB TRR 219"},{"DOI":"10.13039\/100001582","name":"DF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic kidney disease (CKD) is associated with a substantially increased risk for the development of atherosclerotic cardiovascular (CV) disease. Accordingly, CV mortality is increased even in the earliest stages of CKD. In the general population and in CKD patients, high plasma levels of low-density lipoprotein cholesterol (LDL-C) are crucially involved in the initiation and progression of atherosclerotic vascular lesions. Lowering LDL-C by use of statins and\/or ezetimibe represents the gold standard of lipid-lowering therapy, with a great body of evidence from several large clinical trials. Statin therapy reduces CV events in patients with normal and impaired kidney function alike, while the evidence for patients on maintenance haemodialysis is weaker. The inhibition of proprotein convertase subtilisin\/kexin type 9 (PCSK9) serine protease represents a novel lipid-lowering tool. Currently the monoclonal antibodies evolocumab and alirocumab are the approved PCSK9 inhibitors. Despite maximum-tolerated statin therapy, they efficiently further reduce LDL-C plasma levels without any major adverse effects. Moreover, in large clinical outcome trials, both antibodies have been proven to lower CV events. Notably, the LDL-lowering capacity was independent of baseline kidney function and also efficient in patients with moderate CKD. However, patients with severely impaired kidney function, that is, the population at the highest CV risk, have been excluded from those trials. The relevance of the LDL-independent effects of PCSK9 inhibitors, such as lowering lipoprotein(a) or ameliorating dyslipidaemia in patients with nephrotic syndrome, has to be determined. Therefore further specific studies assessing the effects and outcomes of PCSK9-inhibiting treatment in CKD patients are warranted.<\/jats:p>","DOI":"10.1093\/ndt\/gfz122","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T07:09:10Z","timestamp":1559286550000},"page":"1266-1271","source":"Crossref","is-referenced-by-count":24,"title":["Proprotein convertase subtilisin\/kexin type 9 in kidney disease"],"prefix":"10.1093","volume":"34","author":[{"given":"David","family":"Schmit","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Centre, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Fliser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Centre, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thimoteus","family":"Speer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Centre, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"2019080503545683700_gfz122-B1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"2019080503545683700_gfz122-B3","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"key":"2019080503545683700_gfz122-B4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"2019080503545683700_gfz122-B6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrneph.2010.157","article-title":"Atherosclerosis in chronic kidney disease: the role of macrophages","volume":"7","author":"Kon","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2019080503545683700_gfz122-B7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"2019080503545683700_gfz122-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-74-1-1","article-title":"Serum cholesterol, lipoproteins, and the risk of coronary heart disease","volume":"74","author":"Kannel","year":"1971","journal-title":"Ann Intern Med"},{"key":"2019080503545683700_gfz122-B9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","article-title":"Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2","volume":"38","author":"Speer","year":"2013","journal-title":"Immunity"},{"key":"2019080503545683700_gfz122-B10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/ndt\/gft080","article-title":"Uraemic dyslipidaemia revisited: role of high-density lipoprotein","volume":"28","author":"Speer","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545683700_gfz122-B11","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehu111","article-title":"Carbamylated low-density lipoprotein induces endothelial dysfunction","volume":"35","author":"Speer","year":"2014","journal-title":"Eur Heart J"},{"key":"2019080503545683700_gfz122-B12","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfv048","article-title":"Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease","volume":"30","author":"Gajjala","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545683700_gfz122-B13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jacc.2016.07.755","article-title":"Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo","volume":"68","author":"Holy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2019080503545683700_gfz122-B14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2019080503545683700_gfz122-B15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"2019080503545683700_gfz122-B16","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 \u00d7 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2019080503545683700_gfz122-B17","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"2019080503545683700_gfz122-B19","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2019080503545683700_gfz122-B20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diab Endocrinol"},{"key":"2019080503545683700_gfz122-B21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2019080503545683700_gfz122-B22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"2019080503545683700_gfz122-B23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"2019080503545683700_gfz122-B25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"2019080503545683700_gfz122-B27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem J"},{"key":"2019080503545683700_gfz122-B28","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"2019080503545683700_gfz122-B29","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B31","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080503545683700_gfz122-B32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","article-title":"Lipid-lowering agents","volume":"124","author":"Hegele","year":"2019","journal-title":"Circ Res"},{"key":"2019080503545683700_gfz122-B33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"2019080503545683700_gfz122-B34","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","article-title":"Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies","volume":"135","author":"Toth","year":"2017","journal-title":"Circulation"},{"key":"2019080503545683700_gfz122-B35","doi-asserted-by":"crossref","first-page":"e002196","DOI":"10.1161\/CIRCGEN.118.002196","article-title":"Genetic assessment of potential long-term on-target side effects of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors","volume":"12","author":"Nelson","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"2019080503545683700_gfz122-B36","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"key":"2019080503545683700_gfz122-B37","volume-title":"Efficacy and Safety of Evolocumab in CKD: Data from the FOURIER Trial","author":"Charytan","year":"2018"},{"key":"2019080503545683700_gfz122-B38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"2019080503545683700_gfz122-B39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ehjcvp\/pvx010","article-title":"Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting","volume":"4","author":"Korman","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2019080503545683700_gfz122-B40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijcard.2017.10.080","article-title":"Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease","volume":"253","author":"Stam-Slob","year":"2018","journal-title":"Int J Cardiol"},{"key":"2019080503545683700_gfz122-B41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","article-title":"A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein(a) levels","volume":"19","author":"Cao","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"2019080503545683700_gfz122-B42","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diab Endocrinol"},{"key":"2019080503545683700_gfz122-B43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11255-018-2047-y","article-title":"The effect of chronic kidney disease on lipid metabolism","volume":"51","author":"Dincer","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2019080503545683700_gfz122-B44","author":"Bittner","year":"2019"},{"key":"2019080503545683700_gfz122-B45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","article-title":"Lipid management in chronic kidney disease: systematic review of PCSK9 targeting","volume":"78","author":"Zheng-Lin","year":"2018","journal-title":"Drugs"},{"key":"2019080503545683700_gfz122-B46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2019080503545683700_gfz122-B47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545683700_gfz122-B48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","article-title":"The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia","volume":"134","author":"Haas","year":"2016","journal-title":"Circulation"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfz122\/28796365\/gfz122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/8\/1266\/29096772\/gfz122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T18:39:17Z","timestamp":1568918357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/8\/1266\/5514238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,6,13]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz122","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,6,13]]}}}